Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial

David Fiorentino, Aaron R. Mangold, Victoria P. Werth, Lisa Christopher‐Stine, Alisa N. Femia, Myron Chu, Amy Musiek, Jason C. Sluzevich, Lauren V. Graham, Anthony P. Fernandez, Rohit Aggarwal, Kerri E. Rieger, Karen M. Page, Xingpeng Li, Craig Hyde, Natalie Rath, Abigail Sloan, Barry S. Oemar, Anindita Banerjee, M.P. Salganik, Christopher Banfield, Srividya Neelakantan, Jean S. Beebe, Michael S. Vincent, Elena Peeva, Ruth Ann Vleugels